瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

已收盘 07-29 16:08:19

46.260

-3.640

-7.29%

最高49.900	最低44.460	成交量35.15万
今开48.980	昨收49.900	日振幅10.90%
总市值78.64亿	流通市值78.64亿	总股本1.70亿
成交额1,615万	换手率0.21%	流通股本1.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":46.26,"timestamp":1785312499313,"preClose":49.9,"halted":0,"volume":351515,"delay":0,"changeRate":-0.07294589178356715,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"已收盘","change":-3.64,"latestTime":"07-29 16:08:19","open":48.98,"high":49.9,"low":44.46,"amount":16152855,"amplitude":0.109018,"askPrice":46.3,"askSize":400,"bidPrice":46.26,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":49.9,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":1.106069,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"1142341313","title":"瑞博生物-B：核心产品vortosiran 2b期全球多区域临床试验获欧洲药管局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1142341313","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142341313?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:11","pubTimestamp":1785240675,"startTime":"0","endTime":"0","summary":"2026年7月28日，苏州瑞博生物技术股份有限公司发布自愿公告称，其核心候选药物vortosiran针对心房颤动患者中风预防的2b期多区域临床试验已获欧洲药品管理局批准启动。瑞博生物-B强调，vortosiran的2b期临床试验获批系项目全球开发的重要里程碑，并将推动其进入下一阶段全球临床开发。不过，公司亦提示，vortosiran最终可能无法成功开发及商业化，提醒投资者审慎决策。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017630","title":"瑞博生物-B(06938.HK)核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654017630?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:01","pubTimestamp":1785240070,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198781631","title":"瑞博生物-B：7月24日回购7.84万股，耗资约422.37万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198781631","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198781631?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:41","pubTimestamp":1784896902,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月24日发布翌日披露报表，公告显示公司于当日回购H股78,400股，约占回购前已发行股本的0.0461%。回购价格介于每股港币52.6元至54.4元之间，总耗资约港币422.37万。公司公告指出，此次回购后，其已发行股本变动为169,985,510股，库藏股数增至569,400股，总股本维持170,554,910股。公司同时确认本次回购已获得董事会正式授权，并遵守香港联交所上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：7月24日回购7.84万股，耗资约422.37万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653821850","title":"瑞博生物-B(06938)7月24日斥资约422.37万港元回购7.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653821850","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653821850?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:40","pubTimestamp":1784896814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年7月24日该公司斥资约422.37万港元回购7.84万股，回购价格为每股52.6至54.4港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082188","title":"瑞博生物-B(06938.HK)7月24日斥资约422.37万港元回购7.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653082188?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:40","pubTimestamp":1784896814,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164611703","title":"瑞博生物公布Vortosiran二期a阶段试验积极数据——全球首份关于siRNA介导的FXI抑制在冠状动脉疾病患者中多次给药后的临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1164611703","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164611703?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:29","pubTimestamp":1784723391,"startTime":"0","endTime":"0","summary":"瑞博生物（RIBOLIFE-B）披露了其候选药物Vortosiran二期a阶段临床试验的积极结果。该数据标志着全球范围内，首次获得关于利用小干扰RNA（siRNA）技术抑制凝血因子XI（FXI），并在冠状动脉疾病患者中经过多次给药后所产生的临床效果信息。\n此次公布的试验数据展现了Vortosiran在目标患者群体中的潜力，为通过创新机制管理血栓风险提供了新的临床证据。该消息对关注前沿生物技术及心血管疾病治疗领域的投资者而言，无疑是一个重要的积极进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103771711","title":"瑞博生物-B 宣布Vortosiran IIa期试验未观察到严重不良事件或大出血事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1103771711","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103771711?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:24","pubTimestamp":1784723053,"startTime":"0","endTime":"0","summary":"瑞博生物-B在Vortosiran的IIa期临床试验中，未观察到任何严重不良事件或大出血事件的发生。这一结果对该公司正在开发的候选药物而言，是一个积极的进展信号。试验数据表明，该药物在受试者中展现出可接受的安全性特征，为进一步的临床研究提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653541227","title":"瑞博生物-B(06938)：FIC小核酸抗凝新药再添重磅新证，重塑治疗格局撬动百亿美元赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2653541227","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653541227?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":"通过靶向FXI，vortosiran降低血栓形成风险，同时保留机体止血功能，有望解决心血管疾病领域的重大未满足医疗需求, 进一步验证vortosiran重塑全球抗凝治疗格局的FIC源头创新价值。例如今年5月，瑞博生物向EMA提交用于治疗CAD的小核酸药物RBD1119的II期临床试验申请。后续公司多款抗凝重磅药的关键数据读出及潜在获批，也将成为瑞博多产品矩阵协同发力，撬动百亿美元全球抗凝赛道，巩固自身FIC领先地位的决定性验证节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174995112","title":"瑞博生物-B公布Vortosiran用于慢性冠状动脉疾病2a期试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174995112","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174995112?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:35","pubTimestamp":1784709351,"startTime":"0","endTime":"0","summary":"2026年7月22日，瑞博生物-B发布自愿公告，披露其核心产品vortosiran在慢性冠状动脉疾病患者中的2a期试验取得积极结果。在完成维持剂量为400 mg的高剂量vortosiran给药后，受试者的凝血因子XI活性平均最大降幅达到92%，且抑制效果持续数月。瑞博生物-B提醒股东及潜在投资者，vortosiran最终可能无法成功开发及商业化，相关人士在买卖公司股份时应审慎行事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653758039","title":"瑞博生物-B(06938)：核心产品VORTOSIRAN针对CAD的2A期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2653758039","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653758039?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:33","pubTimestamp":1784709202,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，公司在上海举行的大国新药全球会议上公布了在欧洲进行的评估vortosiran 针对慢性冠状动脉疾病患者的2a期研究的积极结果。该项试验纳入具有心肌梗死病史且接受阿司匹林治疗的慢性CAD患者。在完成高剂量 vortosiran给药疗程、维持剂量为400 mg的患者中，FXI活性平均最大降幅达到 92%，且在给药后持续数月。通过靶向FXI，vortosiran 旨在降低血栓形成风险，同时保留机体止血功能，有望解决心血管疾病领域的重大未满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)：核心产品VORTOSIRAN针对CAD的2A期积极研究结果","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652400134","title":"瑞博生物-B(06938.HK)7月17日耗资383.2万港元回购7.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652400134","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652400134?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:27","pubTimestamp":1784287622,"startTime":"0","endTime":"0","summary":"格隆汇7月17日丨瑞博生物-B(06938.HK)公告，7月17日耗资383.2万港元回购7.9万股，每股回购价格45.88-50.55港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260717/32311035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141348912","title":"瑞博生物-B：7月17日回购7.9万股，耗资约383.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141348912","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141348912?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:11","pubTimestamp":1784286680,"startTime":"0","endTime":"0","summary":"瑞博生物-B于2026年7月17日公告称，公司当天在香港联合交易所场内回购普通股7.9万股，占回购前公司已发行股份约0.0464%。本次回购价格范围为每股45.88港元至50.55港元，平均价格约48.5111港元，涉及总金额约383.24万港元。公告显示，本次回购后，公司于2026年7月17日的已发行股份数量由170,142,910股减少至170,063,910股，库存股份由412,000股增至491,000股，合计仍为170,554,910股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：7月17日回购7.9万股，耗资约383.24万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162716391","title":"瑞博生物-B 2026年7月16日回购19.78万股，耗资约998.38万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162716391","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162716391?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:16","pubTimestamp":1784200574,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月16日发布翌日披露报表，披露当日通过香港联交所场内回购普通股合计197,800股，占回购前已发行股本的0.1161%。本次回购的价格区间为每股49.98港元至50.55港元，共耗资9,983,758港元，折合约998.38万港元。截至目前，瑞博生物-B已在香港联交所或其他证券交易所总计回购412,000股，占授权通过当日已发行股本的0.2416%，相应剩余可回购股份数量为16,643,491股。公司确认，本次股份购回严格遵守了香港联交所证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B 2026年7月16日回购19.78万股，耗资约998.38万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116851585","title":"瑞博生物-B于7月15日回购6200股，耗资约30.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116851585","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116851585?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:16","pubTimestamp":1784114163,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月15日公布公告，披露公司当日在香港联交所场内回购股份。回购股份数量为6200股，占当日公司现有已发行股本约0.0036%，每股回购价格介乎49.42港元至49.50港元，合计耗资约30.69万港元。本次回购完成后，公司已发行股本总数仍为170,554,910股，库存股份增加至214,200股。本次回购基于股东于2026年6月5日通过的回购授权，公司根据该授权可回购的股份总数为17,055,491股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B于7月15日回购6200股，耗资约30.69万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651245752","title":"瑞博生物-B(06938)7月15日斥资30.69万港元回购6200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651245752","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651245752?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:12","pubTimestamp":1784113967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年7月15日斥资30.69万港元回购6200股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135191334","title":"瑞博生物-B于7月14日回购21,400股，涉资约103.78万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135191334","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135191334?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:56","pubTimestamp":1784026587,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月14日发布公告，披露公司在香港联交所场内回购21,400股H股普通股，约占回购前已发行股份总数的0.0126%。此次回购每股价格介乎48.12港元至48.58港元，总耗资1,037,796港元。公告显示，本次回购完成后，公司已发行股份由2026年7月13日的170,368,310股降至170,346,910股，库藏股数量由186,600股增至208,000股，公司已发行股本总数仍为170,554,910股。公司同时确认，本次回购已获得董事会正式批准，并遵照所有适用的上市规则与相关法律法规进行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B于7月14日回购21,400股，涉资约103.78万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193473629","title":"瑞博生物-B：7月13日回购18.66万股，耗资约930.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193473629","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193473629?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:00","pubTimestamp":1783951258,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月13日发布翌日披露报表，公告显示，该公司于当日在香港联交所场内回购186,600股H股普通股，占公司现有已发行股本约0.1094%。回购价格介乎每股港币47.52元至港币51.45元，合计支付约9,301,200港元。回购完成后，瑞博生物-B已发行股份数为170,554,910股不变，其中所持库藏股由0股变更为186,600股，现有已发行股份数量变动为170,368,310股。瑞博生物-B确认已遵守香港联交所证券上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：7月13日回购18.66万股，耗资约930.12万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195184768","title":"瑞博生物-B（06938）7月13日斥资930.12万港元回购18.66万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195184768","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195184768?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:50","pubTimestamp":1783950655,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司7月13日发布自愿公告称，公司已根据2026年6月5日股东周年大会授予的股份回购授权，于2026年7月13日在公开市场回购186,600股H股，总代价为9,301,200港元。公司董事会表示，股份回购在当前市况下进行，符合公司及全体股东的整体利益，并可能在适当时机在符合法规要求的前提下继续进行。瑞博生物-B提示，具体回购的时间、数量及价格将视市场情况由董事会全权决定，投资者在买卖公司证券时应保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651112475","title":"瑞博生物-B(06938)7月13日耗资930.12万港元回购18.66万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651112475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651112475?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:49","pubTimestamp":1783950591,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)公布，公司于2026年7月13日在公开市场购回合共18.66万股H股，总代价为930.12万港元。所有该等购回的H股均作为库存股份持有。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651980196","title":"瑞博生物-B午后涨近5% 中邮证券给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651980196","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651980196?lang=zh_cn&edition=full","pubTime":"2026-07-13 14:49","pubTimestamp":1783925340,"startTime":"0","endTime":"0","summary":"　　瑞博生物-B盘中涨超6%，截至发稿，股价上涨4.69%，现报50.50港元，成交额1509.60万港元。　　瑞博生物-B发布公告，董事会近日获公司执行董事、联席首席执行官兼全球研发总裁甘黎明博士告知，甘黎明博士以自有资金在公开市场进一步购入6800股公司H股。　　中邮证券发布研报称，给予瑞博生物“买入”评级，公司目前仍处于创新药研发投入阶段，是全球最早布局siRNA药物领域的开拓者之一，多款高潜力在研药物进度领先。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrxcc2196477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06938","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":0.1094},{"period":"3month","weight":-0.1846},{"period":"6month","weight":-0.3164},{"period":"1year","weight":-0.1392},{"period":"ytd","weight":-0.1392}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.1164},{"period":"3month","weight":-0.0307},{"period":"6month","weight":-0.095},{"period":"1year","weight":-0.0098},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司主要从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}